🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Turkey / NCT06457178
Recruiting Not applicable

Investigation of the Effect of Acceptance and Commitment Therapy-Based Intervention in Oncology Patients

NCT06457178 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-06-01
Last updated
2025-06-03

Condition(s) studied

Acceptance and Commitment Therapy

Investigational drug(s) / intervention(s)

Acceptance and Commitment Therapy-Based Intervention for Oncology PatientsPsychoeducation for Oncology Patients

Acceptance and Commitment Therapy-Based Intervention for Oncology Patients: An intervention program was prepared for oncology patients aiming to reduce psychological distress and increase participation in normal life.

Psychoeducation for Oncology Patients: A program was prepared to support oncology patients in physical and psychological symptom management.

Study summary

The goal of this clinical trial is to investigate the effectiveness of Acceptance and Commitment Therapy Based Intervention for Oncology Patients. The main questions it aims to answer are:

* Does the Acceptance and Commitment to Therapy-Based Intervention for Oncology Patients affect the level of psychological distress?
* Does the Acceptance and Commitment to Therapy-Based Intervention for Oncology Patients affect the level of reintegration into normal life?

Researchers will compare Acceptance and Commitment Therapy-Based Intervention for Oncology Patients (ACT) to Psychoeducation for Oncology Patients and routine care (with no specific intervention) to see if Acceptance and Commitment Therapy-Based Intervention for Oncology Patients is effective in psychological distress and reintegration into normal living.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * 18 years of age or older, * Being able to read and write, * Receiving oncologic treatment, * Being diagnosed with breast cancer, * To know about Medical Diagnosis, * Being in stage 1, 2 or 3 of the disease, * Receiving outpatient chemotherapy treatment only, * Internet access and computer skills to participate in online group interviews, * Low to moderate scores on the brief psychological resilience scale, Exclusion Criteria: * Having serious psychiatric or cognitive impairments that limit adherence to group sessions, * Having a physical disability that may make it difficult to participate in group sessions, * Failure to attend sessions regularly and absenteeism, * Currently being in a psychoeducation/psychotherapy group

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Acibadem Hospital Istanbul Turkey (Türkiye) Recruiting

More Istanbul University - Cerrahpasa trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06457178 on ClinicalTrials.gov ↗ ← All trials in Turkey